EUVIMEDEUVIMED entdecken
Fallbericht

Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma

Dimitri Anzellini, Marco Loddo, Sergio Del Bianco

Anticancer Research · 2025

DOI: 10.21873/anticanres.17740 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Anticancer Research, 2025. Verfasst von Dimitri Anzellini und 2 weiteren Autor:innen. Beteiligte Einrichtung: OncoPrecisionClinic, Rome, Italy; drsergiodelbianco@oncoprecision.it. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, GTP Phosphohydrolases, Membrane Proteins, CTLA-4 Antigen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy. Its prognosis is poor, particularly in patients with distant metastasis. Treatment of ATC Is mostly palliative. In this report, we present the case of a patient affected by NRAS Q16R mutated, polymetastatic and multi-treated ATC, who showed complete remission of the disease after the use of an anti-PD1 and anti-CTLA4 doublet. CASE REPORT: We present the clinical case of an 82-year-old patient affected by polymetastatic anaplastic thyroid carcinoma carrying NRAS (Q16R) mutation, treated with surgery, radiotherapy and chemotherapy. Complete and long-lasting disease response was induced to the patient after immunotherapy anti PD1 plus anti CTLA4 (pembrolizumab + ipilimumab). CONCLUSION: The combination of pembrolizumab plus ipilimumab may represent a therapeutic strategy in patients with NRAS (Q16R) mutated anaplastic thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid Carcinoma, AnaplasticGTP PhosphohydrolasesMembrane ProteinsCTLA-4 AntigenThyroid NeoplasmsProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansAged, 80 and overMutationAntibodies, Monoclonal, HumanizedIpilimumabMaleRemission InductionImmunotherapyFemale

Stichwörter der Autor:innen

Anaplastic thyroid cancerNRASPDL1ipilimumabmolecular profilingmolecular residual diseaseoligoprogressiveoligoresistancepembrolizumabtarget therapy

Substanzen

NRAS protein, humanGTP PhosphohydrolasesMembrane ProteinsCTLA-4 AntigenCTLA4 protein, humanProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedpembrolizumabPDCD1 protein, humanIpilimumab

Autor:innen und Institutionen

  • OncoPrecisionClinic, Rome, Italy; drsergiodelbianco@oncoprecision.it.
  • OncologicaUK Ltd, Chesterford Research Park, Cambridge, U.K.
  • OncoPrecisionClinic, Rome, Italy.

Zitieren

APA

Anzellini, D., Loddo, M., & Del Bianco, S. (2025). Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17740

Vancouver

Anzellini D, Loddo M, Del Bianco S. Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma. Anticancer Research. 2025. doi:10.21873/anticanres.17740

BibTeX
@article{Anzellini2025,
  author = {Anzellini, Dimitri and Loddo, Marco and Del Bianco, Sergio},
  title = {Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma},
  journal = {Anticancer Research},
  year = {2025},
  doi = {10.21873/anticanres.17740}
}
Kostenlos starten →